We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Evaluating Acadia Healthcare's Outlook: Hold for Now or Fold?
Read MoreHide Full Article
Key Takeaways
Acadia Healthcare is growing steadily, driven by demand for behavioral health services and facility expansion.
ACHC added beds and joint ventures, boosting revenue growth and positioning for higher occupancy gains.
Rising expenses and weak ROE versus industry peers remain key concerns despite solid growth outlook.
Acadia Healthcare Company, Inc. (ACHC - Free Report) is steadily increasing its business due to rising demand for behavioral health services. Its psychiatric hospitals and treatment centers are performing well. It is also expanding through acquisitions and capacity additions, supporting its long-term growth.
The stock has gained 60.9% year to date against the industry’s 5.9% decline. Both the Zacks Medical sector and the S&P 500 composite have decreased 7.4% in the same time frame.
Image Source: Zacks Investment Research
Zack’s Rank and Valuation of ACHC
Acadia Healthcare currently carries a Zacks Rank #3 (Hold).
From a valuation perspective, Acadia Healthcare appears to be priced at a premium. With a market capitalization of about $2.1 billion, the stock trades at a forward P/E of 15.1X, above the industry average of 9.9X, suggesting a relatively rich valuation compared to peers. The company currently holds a Value Score of B. Image Source: Zacks Investment Research
Where Do Estimates for ACHC Stand?
The consensus mark for 2026 earnings is pegged at $1.48 per share, which has remained unchanged over the past 30 days. The consensus estimate for revenues is pegged at $3.4 billion, indicating 3% year-over-year growth. ACHC’s bottom line surpassed estimates in each of the trailing four quarters, the average surprise being 43%.
Acadia Healthcare Company, Inc. Price, Consensus and EPS Surprise
ACHC’s operating performance has been strong over the years. Its revenue has grown consistently, driven by solid organic growth, steady demand for behavioral health services, and good performance across its core businesses. Its Acute Inpatient Psychiatric Facilities and Comprehensive Treatment Centers remain key growth drivers, with revenues increasing 9.1% and 5.4%, respectively in 2025. The company expects total revenues to reach between $3.37 billion and $3.45 billion in 2026.
In 2025, ACHC added 1,089 beds, including 311 at existing facilities and 778 through new openings. Management is now focused on bringing these new beds to full occupancy. Since most overhead costs are already covered, higher occupancy should generate additional revenues at strong margins. The company also plans to add another 400-600 beds in 2026.
ACHC has built successful partnerships with major health systems. In 2025, it opened five joint-venture facilities with Henry Ford Health, Geisinger Health, Ascension Seton, Fairview Health Services and ECU Health. It also launched 15 Comprehensive Treatment Centers during the year. These joint ventures will help reduce capital risk and provide a steady flow of patients over time.
Acadia Healthcare ended 2025 with cash and cash equivalents of $133.2 million. Its long-term debt-to-capital ratio of 57.7% is lower than the industry average of 74.6%, indicating a relatively healthier balance sheet. Acadia also expects to generate positive free cash flow in 2026, supported by lower capital spending as it shifts focus from expansion toward improving performance at existing sites.
Key Risks to Consider
Despite its growth potential, there are a few concerns investors should consider.
Acadia Healthcare’s total expenses rose 55.7% year over year in 2025, driven by higher salaries, wages and benefits, professional fees, and other operating costs. This rise in expenses may put pressure on the company’s profit margins going forward.
The company’s efficiency remains subdued, with a trailing 12-month ROE of 6.5% compared with the industry average of 25.5%, highlighting weaker return generation versus peers.
Conclusion
Acadia Healthcare shows solid growth prospects supported by strong demand and expansion efforts, but high valuation, rising expenses, and weak efficiency remain key concerns. A wait-and-watch approach seems prudent for now.
The Zacks Consensus Estimate for Phibro Animal Health's 2026 earnings is pegged at $3.03 per share, which moved up 1 cent over the past 30 days, indicating 45% year-over-year growth. The consensus estimate for 2026 revenues is pinned at $1.5 billion, indicating 14.5% year-over-year growth. PAHC beat earnings estimates in each of the trailing four quarters, delivering an average surprise of 20.2%.
The Zacks Consensus Estimate for Catalyst Pharmaceuticals’ 2026 earnings is pinned at $2.87 per share, which moved north 34 cents over the past 30 days. CPRX beat earnings estimates in each of the trailing four quarters, with an average surprise of 35.2%. The consensus estimate for 2026 revenues is pegged at $628.7 million, suggesting 6.7% year-over-year growth.
The Zacks Consensus Estimate for InnovAge's 2026 earnings is pegged at $0.25 per share, which has remained stable over the past 30 days, indicating 213.6% year-over-year growth. The consensus estimate for 2026 revenues is pinned at $944.5 million, indicating 10.6% year-over-year growth. INNV beat earnings estimates in three of the trailing four quarters and missed once, delivering an average surprise of 87.5%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Evaluating Acadia Healthcare's Outlook: Hold for Now or Fold?
Key Takeaways
Acadia Healthcare Company, Inc. (ACHC - Free Report) is steadily increasing its business due to rising demand for behavioral health services. Its psychiatric hospitals and treatment centers are performing well. It is also expanding through acquisitions and capacity additions, supporting its long-term growth.
The stock has gained 60.9% year to date against the industry’s 5.9% decline. Both the Zacks Medical sector and the S&P 500 composite have decreased 7.4% in the same time frame.
Image Source: Zacks Investment Research
Zack’s Rank and Valuation of ACHC
Acadia Healthcare currently carries a Zacks Rank #3 (Hold).
From a valuation perspective, Acadia Healthcare appears to be priced at a premium. With a market capitalization of about $2.1 billion, the stock trades at a forward P/E of 15.1X, above the industry average of 9.9X, suggesting a relatively rich valuation compared to peers. The company currently holds a Value Score of B.
Image Source: Zacks Investment Research
Where Do Estimates for ACHC Stand?
The consensus mark for 2026 earnings is pegged at $1.48 per share, which has remained unchanged over the past 30 days. The consensus estimate for revenues is pegged at $3.4 billion, indicating 3% year-over-year growth. ACHC’s bottom line surpassed estimates in each of the trailing four quarters, the average surprise being 43%.
Acadia Healthcare Company, Inc. Price, Consensus and EPS Surprise
Acadia Healthcare Company, Inc. price-consensus-eps-surprise-chart | Acadia Healthcare Company, Inc. Quote
Business Tailwinds for ACHC
ACHC’s operating performance has been strong over the years. Its revenue has grown consistently, driven by solid organic growth, steady demand for behavioral health services, and good performance across its core businesses. Its Acute Inpatient Psychiatric Facilities and Comprehensive Treatment Centers remain key growth drivers, with revenues increasing 9.1% and 5.4%, respectively in 2025. The company expects total revenues to reach between $3.37 billion and $3.45 billion in 2026.
In 2025, ACHC added 1,089 beds, including 311 at existing facilities and 778 through new openings. Management is now focused on bringing these new beds to full occupancy. Since most overhead costs are already covered, higher occupancy should generate additional revenues at strong margins. The company also plans to add another 400-600 beds in 2026.
ACHC has built successful partnerships with major health systems. In 2025, it opened five joint-venture facilities with Henry Ford Health, Geisinger Health, Ascension Seton, Fairview Health Services and ECU Health. It also launched 15 Comprehensive Treatment Centers during the year. These joint ventures will help reduce capital risk and provide a steady flow of patients over time.
Acadia Healthcare ended 2025 with cash and cash equivalents of $133.2 million. Its long-term debt-to-capital ratio of 57.7% is lower than the industry average of 74.6%, indicating a relatively healthier balance sheet. Acadia also expects to generate positive free cash flow in 2026, supported by lower capital spending as it shifts focus from expansion toward improving performance at existing sites.
Key Risks to Consider
Despite its growth potential, there are a few concerns investors should consider.
Acadia Healthcare’s total expenses rose 55.7% year over year in 2025, driven by higher salaries, wages and benefits, professional fees, and other operating costs. This rise in expenses may put pressure on the company’s profit margins going forward.
The company’s efficiency remains subdued, with a trailing 12-month ROE of 6.5% compared with the industry average of 25.5%, highlighting weaker return generation versus peers.
Conclusion
Acadia Healthcare shows solid growth prospects supported by strong demand and expansion efforts, but high valuation, rising expenses, and weak efficiency remain key concerns. A wait-and-watch approach seems prudent for now.
Key Picks
Some better-ranked stocks in the broader Medical sector are Phibro Animal Health Corporation (PAHC - Free Report) , Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) and InnovAge Holding Corp. (INNV - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Phibro Animal Health's 2026 earnings is pegged at $3.03 per share, which moved up 1 cent over the past 30 days, indicating 45% year-over-year growth. The consensus estimate for 2026 revenues is pinned at $1.5 billion, indicating 14.5% year-over-year growth. PAHC beat earnings estimates in each of the trailing four quarters, delivering an average surprise of 20.2%.
The Zacks Consensus Estimate for Catalyst Pharmaceuticals’ 2026 earnings is pinned at $2.87 per share, which moved north 34 cents over the past 30 days. CPRX beat earnings estimates in each of the trailing four quarters, with an average surprise of 35.2%. The consensus estimate for 2026 revenues is pegged at $628.7 million, suggesting 6.7% year-over-year growth.
The Zacks Consensus Estimate for InnovAge's 2026 earnings is pegged at $0.25 per share, which has remained stable over the past 30 days, indicating 213.6% year-over-year growth. The consensus estimate for 2026 revenues is pinned at $944.5 million, indicating 10.6% year-over-year growth. INNV beat earnings estimates in three of the trailing four quarters and missed once, delivering an average surprise of 87.5%.